Document is current
Any future updates will be listed below
-
Authors
Yoneyama, Fumiya
Fujita, Naoki https://orcid.org/0000-0001-8284-9582
Kawashima, Yohei
Shinohara, Masanao
Tabata, Ryuji
Tanaka, Ryuma
Oishi, Takuya
Miura, Hikari
Togashi, Kyo
Okita, Kazutaka
Horiguchi, Hirotaka
Tanaka, Toshikazu
Noro, Daisuke
Suzuki, Yuichiro
Sato, Satoshi
Ohyama, Chikara
Hatakeyama, Shingo
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (25K12244)
- License Information
-
More Information
Article History
Received: 13 April 2025
Accepted: 29 June 2025
First Online: 8 July 2025
Declarations
:
: Shingo Hatakeyama received honoraria from Janssen Pharmaceutical K.K., Astellas Pharma Inc., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Bayer AG, Pfizer Inc., Bristol-Myers Squibb, Merck Biopharma Co., Ltd., Kaneka Corporation, and Nipro Corporation. The other authors have no conflicts of interest to declare.
: This study adhered to the principles of the Declaration of Helsinki and was approved by the ethics committees of the Hirosaki University Graduate School of Medicine (authorization number: 2019-099-1 and 2021-158-2) and all participating hospitals.
: The requirement for written informed consent was waived because of the use of a public disclosure of study information (opt-out approach).
